Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,704.00+4.80%ETH$2,426.56+7.03%GOLD$4,092.80+0.49%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
LU

NASDAQ · LUNG

Pulmonx Corporation

Healthcare · Medical - Devices

$2.72

Up+$0.11 (+4.04%)

Updated Nov 5, 2026, 12:54 AM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
103.73M
P/E ratio
-1.78
Dividend yield
0.00%
52-week range
$1.13 – $3.25
Volume
747.7K
Avg. volume
2.59M

Price performance · LUNG

LUNG price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

LUNG closed at $2.72 after 20 trading sessions, up 47.83% for the selected period.

Last close
$2.72
Period change
+47.83%
Period low
$1.75
Period high
$3.17
Daily close
View OHLC price history
LUNG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$2.58$2.7758$2.58$2.72747.7K
Nov 2, 2026$3.04$3.13$2.50$2.581.44M
Oct 30, 2026$3.13$3.23$2.79$3.0052.41M
Oct 29, 2026$2.61$3.25$2.53$3.1655.37M
Oct 28, 2026$2.37$2.77$2.31$2.527.28M
Oct 27, 2026$1.99$2.025$1.92$1.98490.99K
Oct 26, 2026$1.81$1.97$1.79$1.95641.55K
Oct 23, 2026$1.80$1.88$1.79$1.83227.77K
Oct 22, 2026$1.81$1.89$1.81$1.88131.55K
Oct 21, 2026$1.82$1.86$1.82$1.83176.68K
Oct 20, 2026$1.75$1.855$1.75$1.82525.79K
Oct 19, 2026$1.80$1.80$1.745$1.75220.31K
Oct 16, 2026$1.85$1.875$1.755$1.78243.99K
Oct 15, 2026$1.77$1.88$1.77$1.85268.12K
Oct 14, 2026$1.80$1.80$1.72$1.78285.31K
Oct 13, 2026$1.79$1.865$1.74$1.76498.61K
Oct 12, 2026$1.81$1.93$1.74$1.80428.72K
Oct 9, 2026$1.81$1.90$1.81$1.84204.44K
Oct 8, 2026$1.84$1.84$1.775$1.81229.16K
Oct 7, 2026$1.75$1.9053$1.75$1.84379.73K

Latest LUNG news

The latest Smart Investors Daily articles mentioning LUNG.

Stock researchCompany · Overview

LUNG research

Overview

Company profile and research snapshot.

Company profile

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.25
Implied upside
—
Analysts
—
LUNG recent ratings
DateFirmRatingTarget
Oct 28, 2026StifelBuy—
Apr 30, 2026D. Boral CapitalBuy—
Mar 5, 2026Canaccord GenuityBuy—
Mar 5, 2026D. Boral CapitalBuy—
Feb 20, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Pulmonx to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumFormat: Fireside chat and 1x1 meetingsDate: Wednesday, November 11Fireside Chat Time: 9:30 AM – 9:55 AM ET Stifel 2026 Healthcare ConferenceFormat: Fire

Yahoo · Oct 27, 2026

What Pulmonx (LUNG) Said on Its Q3 Earnings Call

Pulmonx (NASDAQ:LUNG) reported third-quarter revenue growth and a narrower loss as the company cited progress in rebuilding its U.S. sales organization, tightening expenses and advancing clinical programs intended to expand its market. Total worldwide revenue for the quarter ended Sept. 30 was $22.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By